Advertise on podcast: The Doctor's Lounge

Send us Fan Mail Episode Summary This episode examines why US healthcare keeps rewarding consolidation, even when it raises costs and makes the system harder to navigate. Andrew Tsang, writer of Health is Other People, brings a cross-industry view from consulting, policy, providers, and payers to explain how hospitals, insurers, and Medicare rules all shape behavior. We discuss why the system feels adversarial, how incentives drive consolidation, and why policies like the No Surprises Act and MLR can produce unintended consequences. The conversation also turns into a broader argument that the real problem may be cultural and existential, not just technical or legislative. Timestamps 00:00 - Introducing Andrew Tsang and his healthcare writing background 00:53 - From consulting and Medicaid work to healthcare writing 03:10 - Why hospitals are political systems, not just businesses 05:23 - Mass General Brigham, consolidation, and incentive-driven growth 10:20 - What the No Surprises Act is trying to do for patients 12:39 - Independent dispute resolution and the provider payer dynamic 15:49 - Why arbitration may favor providers and still raise costs 18:26 - MLR, insurer incentives, and the limits of cost containment 22:19 - Why US healthcare fights over scarce resources instead of throughput 23:46 - The scale of utilization management and billing conflict 24:23 - Medicare DRGs, coding complexity, and upcoding incentives 26:24 - How hospital market power affects commercial pricing 28:28 - What actually drives merger strategy inside health systems 31:39 - Why insurers and hospitals still claim cost control while behaving differently 37:37 - The Tufts and Partners negotiation as a lesson in market power 40:33 - Essential benefits, narrow plans, and how coverage rules shape leverage 44:42 - Why the US wants both public guarantees and private market incentives 47:11 - Vertical integration in insurance and why it is rewarded 53:39 - Why policy fixes are incremental and often politically compromised 56:21 - Why Andrew left consulting and what felt futile about the work 58:18 - The case for healthcare as a cultural and moral problem 59:12 - Why selfishness, greed, and apathy may be the real barriers to reform Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Mr. Andrew Tsang LinkedIn: linkedin.com/in/tsang1219 Mr. Andrew Tsang Substack handle is:  https://substack.com/@andrewtsang Mr. Andrew Tsang Substack Health is Other People link:  https://blog.healthisotherpeople.com/?utm_source=global-search Mr. Andrew Tsang Substack Mass General Brigham merger link: https://substack.com/@andrewtsang/note/c-350273328?utmSource=%2Fsearch%2FMass%2520General%2520Brigham%2520merger 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary  Dr. Mollie James joins Anish Koka, MD and Anthony DiGiorgio to talk about what pushed her out of traditional employment, how she rebuilt her practice after bankruptcy and COVID, and why she believes more physicians need independent options. The conversation focuses on the pressures of hospital employment, the power of pricing and cash pay, and practical paths for doctors who want more autonomy. Timestamps (00:00) Dr. Mollie James' background and the goal of the conversation (01:41) Southern Iowa roots, DO training, surgery, ICU work, and leaving academics (03:19) Administrative overload and trying to rebuild trauma services after a tornado (04:43) Why job-hopping did not solve the real problem (07:11) RVU pressure, too few ORs, and the impossible math of employed surgery (08:29) Why administrators miss the clinical big picture (09:59) The COVID straw that broke the camel's back (11:49) Pushback over medication choices and committee control (13:45) Launching James Clinic during the pandemic (16:17) Treating 4,000 COVID patients in four months (17:30) Telemedicine, a low-rent clinic, and building from scratch (18:23) Cash pricing, two-week coverage, and tiered support (19:46) Doubters, happy hypoxia, and why outpatient COVID care worked (21:32) The treatment approach: steroids, antihistamines, and more (23:24) ICU COVID, sedation, vent intolerance, and prolonged intubations (25:51) Omicron, collapsing COVID volume, and pivoting the business (27:30) Pricing mistakes, layoffs, and how a practice has to evolve (28:10) Why the integrative cancer program was underpriced (29:28) Current niches: hormone care, blood pressure, fatigue, mitochondrial support (30:12) Why the market can solve care shortages better than administration (31:46) Why cash pay and patient-funded care reduce conflict over evidence (35:48) Independent medicine requires results, service, and rapid feedback (36:42) Why low prices can limit your ability to help anyone (37:24) Why physicians should consider independence and self-funded models (40:01) Diversifying privileges and not putting all your eggs in one basket (40:52) How a new grad can start as a 1099 contractor (42:39) Networking, call coverage, and building cooperative physician relationships (43:22) Why scarcity thinking hurts doctors outside the hospital (44:56) The modifier 25 and CMS reimbursement frustrations (46:28) Fear, pricing transparency, and why patients and doctors both lose (47:42) Knowledge replacing fear in healthcare decisions (49:46) Why splitting procedures across days feels absurd to patients (50:48) The real mechanism problem behind billing rules (53:26) Social media manipulation, CPT complexity, and administrative bloat (55:08) Why single payer does not actually mean simple (56:03) Maverick Medical Ventures and the playbook for leaving the system (58:28) Headwinds, hospital consolidation, and patients seeing huge price jumps (60:15) Monopolization, referrals blocked by system rules, and loss of access (61:11) Why hospital privileges can still be a barrier for outpatient procedures (62:10) Culture wars, division, and the need to align on shared physician priorities (64:46) Closing details: James Clinic locations, Maverick Medical, and Dr. James' handle Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Dr. Mollie James X Handle @molsjames Dr. Mollie James Website https://maverickmedicalventures.com/ 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Summary In this episode, Anthony DiGiorgio and Anish Koka engage with Tom Wolf, a recovery advocate, who shares his personal journey through addiction, homelessness, and eventual recovery. The conversation delves into the complexities of homelessness, the impact of substance use, and the evolving definitions and policies surrounding addiction treatment. Tom discusses the harm reduction approach, its origins, and its implications, while emphasizing the need for accountability and the role of physicians in addressing the opioid crisis. The episode highlights the importance of lived experiences in shaping drug policy and the ongoing challenges faced by individuals in recovery. In this conversation, Anthony DiGiorgio and Tom Wolf delve into the complexities of addiction treatment, mental health, and the political landscape surrounding these issues. They discuss the challenges of psychiatric holds, the balance between autonomy and compulsion in treatment, and the failures of current drug policies in major cities. The dialogue emphasizes the need for a recovery-oriented system of care and critiques the harm reduction approach, drawing comparisons to international policies, particularly in Portugal. The conversation highlights the intersection of mental health and addiction, the political ramifications of policy failures, and the urgent need for effective solutions to the ongoing drug crisis. Chapters 00:00 Introduction to Recovery Advocacy 00:55 Tom Wolf's Journey Through Addiction 06:33 Finding Recovery and Advocacy 10:08 The Complexity of Homelessness and Addiction 11:22 The Evolving Definition of Homelessness 12:26 The Impact of Substance Use on Housing 15:06 Harm Reduction: A Double-Edged Sword 20:30 The Role of Physicians in Substance Abuse 25:02 The Historical Context of Opioid Prescription 30:02 The Future of Drug Policy and Recovery 34:39 Navigating Psychiatric Holds and Treatment Options 38:30 The Dilemma of Autonomy vs. Compulsion in Treatment 40:40 Evaluating Policy Failures in Major Cities 44:51 Building a Recovery-Oriented System of Care 47:39 Comparing Drug Policies: Lessons from Portugal 49:40 The Intersection of Mental Health and Addiction 51:51 The Political Landscape of Addiction Recovery 56:55 The Challenges of Acknowledging Policy Failures Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Guest Handle/Links @Twolfrecovery https://www.tomwolfrecovery.com/ Subscribe Links Spotify: http://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary  Rachel Rosenthal, an editorial board member at Bloomberg who writes on healthcare and education, joins Anthony DiGiorgio and Anish Koka for a wide-ranging conversation about healthcare reporting, COVID-era lessons, and why Medicare’s fiscal path matters beyond policy circles. The discussion gets into the incentives behind drug pricing, the limits of simplistic villains in healthcare, and why trade-offs, not slogans, are what actually shape reform. In this episode, Rachel shares how an accidental path from Asia and immigration policy led her into healthcare editorial writing, why the beat is both endlessly frustrating and endlessly rich, and how COVID in Singapore changed the way she thinks about public health authority, institutional trust, and policy mistakes. The conversation also turns to her Bloomberg piece on Medicare, where the hosts unpack how spending, deficits, borrowing, and bond markets connect. Timestamps 00:00 - Intro and guest introduction 00:51 - Rachel’s accidental path from Asia to healthcare writing 03:25 - Why healthcare is a “gift that keeps on giving” 04:57 - From Medicare to digital twins, the range of the beat 06:48 - Why healthcare has no single villain 08:17 - The real work behind strong healthcare editorials 10:04 - How COVID in Singapore changed her perspective 11:40 - Lockdowns, surveillance, and zero-COVID enforcement 14:30 - What the pandemic revealed about institutions and trust 18:18 - Why Singapore’s approach was understandable, then failed to adapt 20:18 - Writing columns that forced policy change 23:46 - How school closures exposed institutional dysfunction 24:38 - Leadership failures and the need for honesty 26:47 - Why source diversity matters in journalism 29:35 - The pressure to publish fast and simplify complex stories 31:04 - Are readers, editors, and advertisers all part of the problem? 35:18 - Why Medicare is the next major fiscal crisis 36:38 - The “one dollar in, three dollars out” problem 39:34 - Why uncapped spending removes urgency 40:04 - Site-neutral payments and other low-hanging fruit 41:31 - Why wealthy seniors still receive subsidies 43:33 - How entitlement reform gets politically messy 45:41 - Why Medicare matters to bond traders 47:01 - Interest rates, mortgages, and everyday life 48:30 - Demographics, aging, and the scale of the problem 49:22 - Why Medicare for All doesn’t solve the deficit 52:06 - Medicare’s complexity and the limits of copying it 55:52 - A simple framework: government choices versus private choice 57:57 - Who decides preventive care coverage and why that is political 59:45 - Health policy as a value judgment, not pure math 62:12 - Rachel’s ideal direction: less employer-sponsored distortion, more individual choice 64:54 - Defining the real problem before designing reform 66:27 - Trade-offs, privilege, and the appeal of security 68:01 - Why innovation in delivery and payment still matters 69:14 - Why good-faith debate disappears when the frame becomes good versus evil 71:07 - Why both left and right need to give ground 72:35 - Universal catastrophic coverage as a possible compromise 73:35 - Security, coverage gaps, and the need for on-ramps between programs 74:32 - Wrap-up and final thoughts Co-Host Handles @anish_koka and @DrDiGiorgio Show handle @DRsLoungePod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail In this special add-on episode, Anish Koka and Anthony DiGiorgio welcome Dr. James O'Leary — a Mayo-trained OB-GYN with forty years of experience, former department chairman, ACO board member, and host of the Real Doc Speaks podcast — for a wide-ranging conversation on the erosion of physician-led care. The trio dissects a tragic Nashville case in which four outpatient knee-replacement patients were injected with potassium phosphate instead of bupivacaine after a multi-step, multi-person medication-verification process failed at every checkpoint, using it as a jumping-off point to discuss "kludgeocracy," alert fatigue, surgical-timeout mission creep, and how doctors who raise safety concerns get labeled disruptive. From there the conversation moves through OB-GYN malpractice and nuclear jury verdicts, Florida's no-fault birth-injury compensation fund as a possible national model, the maze of state-by-state Medicaid reimbursement and its perverse incentives, and nonprofit hospitals' use of stadium sponsorships as a possible anti-kickback violation, before closing with a rapid-fire "hot seat" round covering ACOs, private equity, scope of practice, physician unionization, and single-payer healthcare. Chapters 00:00 Cold open — why isn't Medicaid money reaching physicians? 00:34 Welcoming Dr. James O'Leary (Real Doc Speaks) 02:34 Why physicians need a voice on social media 03:14 The Nashville potassium phosphate medication error 09:52 Would a physician-owned hospital have prevented this? 10:17 "Kludgeocracy" and getting labeled disruptive 14:30 The surgical timeout's mission creep 19:35 EMR alert fatigue and lost safety signals 22:50 Replacing pharmacy techs with better safeguards 24:34 Anish's shift from hospital to outpatient practice 30:19 Malpractice, nuclear verdicts, and OB-GYN 33:50 Florida's no-fault birth-injury compensation model 39:16 Medicaid reimbursement and state-by-state variation 50:33 Nonprofit hospitals, sports sponsorships, and the anti-kickback statute 55:46 Five hot-seat questions for Dr. O'Leary 1:01:51 Direct referrals vs. large health systems 1:03:23 Closing thoughts and where to find Dr. O'Leary Co-Host Handles @anish_koka and @drdigiorgio Guest Handle Dr. James O'Leary — @realdocspeaks Show Handle @drsloungepod Subscribe Links:  Spotify: http://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary Anthony DiGiorgio and Anish Koka speak with Dr. Ashish Jha, co-founder and CEO of BioRadar, senior fellow at Harvard Belfer Center, and former White House COVID-19 response coordinator, about the future of American healthcare policy. The conversation moves from hospital pricing and insurance design to Medicaid, HSA-based models, and the political realities that shape what reform is actually possible. They also pivot into a second major topic: biothreat detection. Jha explains why he thinks biosurveillance, not just response, will be essential in an era of AI-assisted biological engineering. Timestamps 00:00 - Intro, guest credentials, and the Boston Globe cost cure series 00:33 - Why Jha wrote a 10-part reform series instead of one op-ed 01:54 - Evidence-based ideas that should annoy someone on every side 03:42 - Why state-level health policy matters, not just Washington 04:20 - American healthcare’s core pricing problem 05:58 - Competition, monopolies, and when price regulation enters the picture 06:57 - Scope of practice, insurance design, and administrative burden 08:40 - Indiana’s Medicaid-based hospital pricing experiment 09:47 - Why provider price caps are controversial 11:42 - Site-neutral payments and the hospital lobbying problem 13:30 - Why temporary regulation can bridge a monopoly-heavy market 16:22 - Why payer competition matters before price caps can reach consumers 17:44 - Can temporary government policies ever really be reversed? 20:11 - Tackling the demand-side subsidies that fuel consolidation 22:39 - FTC enforcement and the slow pace of market change 23:53 - Why policy experts should give leaders workable alternatives 26:27 - Hospitals are not villains, but incentives matter 27:32 - Site-neutral payment and physician-owned hospitals as starting points 28:57 - Cash payments, deductibles, and value-based insurance design 29:49 - The outline of a possible deal among hospitals, insurers, and policymakers 33:34 - Medicaid work requirements and what the evidence says 35:36 - Why eligibility should be easier for people who qualify 38:02 - Medicaid as a value statement about universal coverage 40:19 - Program integrity, fraud, and long-term sustainability 43:43 - Why Jha changed his mind on pay-for-performance and EHRs 45:14 - His critique of quality metrics and the value of empirical humility 46:14 - Why HSAs are attractive but imperfect 47:23 - Living under an HSA and why behavior changes 49:47 - Why Medicare for All is politically and operationally hard 50:41 - Uwe Reinhardt, Denmark, and why systems depend on politics and people 53:18 - Why sick people often make irrational cost decisions 57:02 - Smarter copays, true emergencies, and the limits of consumerism 58:24 - Why disagreement should stay respectful and not personal 60:20 - Pivot to bioterrorism and biological weapons 61:07 - Why BioRadar was created and what problem it is solving 63:18 - AI, state actors, and the shrinking barrier to bioweapons 64:18 - Why the risk of an engineered pathogen in the next five years worries Jha 65:31 - Jha’s view that COVID was more likely a lab leak than a natural origin 66:30 - Guardrails around gain-of-function research and Fauci criticism 68:46 - The difference between a dangerous outbreak and a stealth pandemic 71:38 - How biosurveillance can avoid overreaction while still catching real threats 73:13 - Why better surveillance could have changed the COVID response 75:16 - Wrap-up, bipartisanship, and the value of trade-offs Co-Host Handles @anish_koka and @DrDiGiorgio Show Handle @DRsLoungePod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary  In this episode of the Doctor's Lounge, Anthony DiGiorgio speaks with Hon. Tom Oliverson, MD, Texas State Representative for House District 130 and chair of the House Republican Caucus. Dr. Oliverson shares how he moved from medicine into public service, why practicing physicians should remain involved in policymaking, and what Texas is doing to address healthcare affordability. They also dig into 340B, prior authorization reform, and the origins of the No Surprises Act. Chapter Markers 00:00 - Introduction to Dr. Tom Oliverson and his Texas healthcare policy role 01:24 - From Cut and Shoot to Baylor and a medical career 05:01 - Why running for office felt like a calling 08:02 - Why Texas lawmakers are expected to keep real jobs 13:30 - The healthcare affordability committee and the expert testimony it drew 16:28 - Consolidation as a major driver of healthcare cost growth 18:49 - Why direct contracting may replace traditional networks 22:49 - What the future could look like in a Singapore-style transparent market 23:53 - ERISA limits, state authority, and the frustration of federal preemption 25:17 - Medicaid payment, fraud, and what states can still influence 28:06 - Using Medicaid buying power to push back on abusive pharmacy practices 29:15 - 340B as a “Robin Hood” program with perverse incentives 36:03 - Why Texas is pushing transparency on 340B revenue and pricing 37:38 - The gold carding law and prior authorization reform 43:43 - A Capitol cardiac arrest and a real-life case with Dr. Bonnen 46:35 - What Texas can and cannot regulate in state insurance markets 48:47 - Texas roots of the No Surprises Act 51:43 - How Texas arbitration was designed to define fair market value 54:25 - Why the federal NSA lost key guardrails 61:41 - Texas opt-in for ERISA plans and why that matters 66:49 - Cash deductible credit when patients choose cheaper care 68:45 - Compounding, GLP-1 dosing, and preserving access through customization 70:09 - Peptides, prevention, food access, and the case for lifestyle-based care 72:34 - Closing thoughts on free markets, 340B, and healthy food Co-Host Handles @anish_koka and @DrDiGiorgio Show Handle @DRsLoungePod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658  YouTube: https://www.youtube.com/@TheDoctorsLoungePod Official Texas House Select Committee on Health Care Affordability page: https://house.texas.gov/committees/committee/059 Dr. Tom Oliverson on X: https://x.com/TomOliverson 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail The prior uploaded file had 26 seconds that was corrupted.  Restored on this version! Episode Summary: Dr. Vinay Prasad joins the Doctors Lounge in a recorded in person conversation that moves from his time at the FDA to bigger questions about evidence, incentives, and trust in medicine. The discussion focuses on how regulatory agencies actually function, why public health debates have become so politicized, and whether the current healthcare funding model rewards good care or just expensive care. Timestamps: 00:16 - Why the FDA conversation matters now 02:49 - Why Vinay accepted the DC job 04:02 - What can actually change inside the FDA 05:39 - The Exondys approval and commissioner authority 07:22 - Do appointees really steer regulatory decisions? 09:48 - Should the FDA regulate safety or efficacy? 10:31 - Safety, efficacy, and the car analogy 13:04 - Could COVID vaccines have been released earlier? 14:04 - Challenge trials versus large community trials 16:32 - Rolling out vaccines by age and risk 18:05 - Why post COVID myocarditis comparisons are flawed 22:36 - The danger of elite stamped misinformation 24:06 - When medicine became political 26:24 - Why institutions may be too captured to trust 27:24 - The measles death story and missing context 30:17 - Buchanan, Tullock, and the logic of bureaucracy 33:17 - How healthcare swallows trillions with mixed value 35:02 - Why low back surgery is hard to centralize 37:27 - ICD placement and gray zone medicine 39:07 - Who should pay for marginal cancer drugs? 41:10 - Demand subsidies and distorted prices 43:34 - Innovation before large welfare programs 46:53 - Does more money always mean more innovation? 48:48 - Why journalism misses what matters at FDA 51:21 - The No Surprises Act and who really pays 55:42 - Vinay’s broader career path and what comes next 57:34 - Why active clinical practice still matters Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Dr. DiGiorgio's project "Off Label Ideas" https://www.offlabelideas.com/ Dr. DiGiorgio's on Substack https://substack.com/@drdigiorgio 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary Duke political economist and podcast host Mike Munger (The Answer is Transaction Costs) joins Anthony DiGiorgio and Anish Koka to argue that what Americans call "health insurance" isn't insurance at all — it's a social program where, as Bastiat put it, everyone tries to live at the expense of everyone else. Munger walks through why Medicare functions as a bilateral monopoly rather than a market, compares the U.S. system to Germany's competitive-insurer model and Chile's subsidized-private-account system, and lays out the four ways any society rations scarce goods — queuing, price, lottery, or authority — arguing the U.S. has mostly abandoned price in favor of blunt instruments like certificates of need. The conversation moves through Kenneth Arrow's 1963 uncertainty paper, the RAND cost-sharing experiment, insurer and provider consolidation, the tax exclusion for employer health benefits, and closes on a bleak but pointed read of federal debt, entitlement insolvency, and why Munger thinks the ship on real reform has already sailed. Chapter Markers 00:00 Introduction and welcome 00:58 Why Medicare isn't really insurance 05:40 Comparing the German, English, and Singaporean models 08:38 Medicare for All as a bilateral monopoly 12:25 Demand-side subsidies and the Learjet story 15:03 Value vs. demand — the Medicaid bariatric surgery example 17:56 Certificates of need and rationing without price signals 21:55 The four ways to ration scarce goods 26:41 The RAND experiment and the cost-sharing debate 28:41 Kenneth Arrow's uncertainty paper and market failure 34:16 How Germany decides what to pay doctors 36:05 Mandatory insurance and adverse selection 38:41 Federalism and state-level insurance regulation 41:04 Provider consolidation and the competition problem 45:18 The employer health benefit tax exclusion 46:27 Federal bureaucracy, DOGE, and cutting government 50:13 Medicare and Social Security insolvency 52:24 "Medicare for All" — the punchline 54:59 Closing thoughts: fee-for-service experiments at the margins Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658  YouTube: https://www.youtube.com/@TheDoctorsLoungePod Dr. Michael Munger on X: @mungowitz Dr. Michael Munger: The Answer Is Transaction Costs podcast links Apple Podcasts: https://podcasts.apple.com/us/podcast/the-answer-is-transaction-costs/id1687215430 Buzzsprout: https://taitc.buzzsprout.com Spotify: https://open.spotify.com/show/05V1tglrMa3ANs0r89OXXg 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary With scheduled guest Dr. Geoff Manley pulled away by a medical emergency, hosts Anish Koka and Anthony DiGiorgio turn the episode into a news roundtable. They open on a JAMA op-ed by Neil Khosla and Ezekiel Emanuel arguing AI will replace physicians outright, and push back on both the regulatory timeline and the incentive structure behind it — including why hospitals are slow to adopt AI tools that already exist, like AI scribes and pre-charting. From there they dig into Medicaid: Michigan's $350 million in new staffing costs tied to One Big Beautiful Bill work requirements, the distortions created by the 90% FMAP for expansion populations, Medicaid fraud recovery data, and Anthony's "food stamps for healthcare" pitch for a cash-equivalent alternative. They close by dismantling the widely cited claim that Medicare for All would save 155,000 lives a year, walking through the underlying studies and what randomized data actually shows about insurance and mortality. Chapter Markers 00:16 Introduction and the JAMA op-ed on AI replacing physicians 07:04 Regulatory hurdles to replacing physicians with AI, and billing codes for AI-assisted care 10:08 Why hospitals aren't adopting AI tools that already exist — scribes and pre-charting 17:01 Healthcare's unlimited demand at zero price 18:53 Michigan Medicaid's $350 million work-requirement staffing costs 22:09 How administratively complex Medicare really is 27:27 Medicaid expansion, the 90% FMAP, and state incentives 31:51 The case for "food stamps for healthcare" — a cash-equivalent Medicaid alternative 37:05 Medicaid fraud control units and state-level innovation 40:41 Debunking the 155,000-lives Medicare for All claim 52:21 Medicare for All and the future of private practice 55:34 Wrap-up and next week's guest preview Co-Host Handles @anish_koka and @drdigiorgio  Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod  🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary In a special Tuesday episode, Anish Koka and Anthony DiGiorgio sit down with Heather Tereshko, a Principal at Post & Schell in Philadelphia and a 25-year veteran of medical malpractice defense, to break down the largest medical malpractice verdict in Pennsylvania history — a $207 million judgment against the University of Pennsylvania stemming from a delayed C-section and resulting anoxic brain injury. Using the case as a launching pad, the three walk through how verdict slips are constructed, why Pennsylvania's "increased risk of harm" standard makes cases easier for plaintiffs to win, how EMR documentation gets weaponized against physicians on the stand, how life-care-plan and non-economic damages get inflated (including "anchoring" tactics like invoking Jalen Hurts's salary), and why juries so often disregard clinical guidelines in favor of narrative and sympathy. The conversation closes with a practical, if sobering, discussion of what physicians could realistically lobby for — tighter expert witness standards, damage caps, and organized legislative pressure — and why none of it is coming easily. Chapter Markers 00:19 Special Tuesday episode and guest introduction: Heather Tereshko 03:22 Heather's background in malpractice defense 05:40 The $207M Penn verdict: how the case started 09:20 Why this is a typical "bad baby" case 11:49 EMR drop-downs and documentation gaps at the center of the case 14:45 The cord blood dispute and the mechanism-of-injury fight 16:01 Judge excludes key testimony on the blood draw 18:33 Inside the verdict slip: factual cause vs. increased risk of harm 25:50 Why "increased risk of harm" doesn't fit this case 27:20 The "team theory" of liability and how the verdict sheet was structured 31:39 Breaking down the $207M damages award 33:06 The life expectancy fight: 29 years vs. 70 years 36:20 Anchoring tactics and the Jalen Hurts salary comparison 39:21 How contingency fees work in Pennsylvania 42:04 "There's no winning": defensive medicine and no-win scenarios 45:14 When health system interests diverge from the individual physician's 46:25 Downstream effects: why community hospitals drop OB services 47:39 No-fault alternatives: New Zealand and Florida's birth injury fund 51:57 Expert witness accountability — or the lack of it 55:58 Venue selection and how it reshaped Philadelphia verdicts 59:04 Damage caps and why economic damages remain unbounded 1:01:54 What physicians can realistically lobby for 1:06:06 Closing thoughts Substack References (Dr. Anish Koka) Referenced during the episode — Anish's Substack posts on the Pennsylvania medical malpractice market and on the Penn ($207M) verdict: PA malpractice market / NAIC data post: https://anishkokamd.substack.com/p/pennsylvania-had-a-functioning-medical Penn verdict case breakdown post: https://anishkokamd.substack.com/p/twelve-people-three-hours-a-207-million Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary Anish Koka and Anthony DiGiorgio sit down with Niklas Anzinger, a venture capitalist and founder of Infinita VC, to unpack Montana SB535 — a new law that lets doctors administer treatments to patients that have only cleared FDA phase one trials, through licensed "experimental treatment centers" overseen by independent review boards. The conversation covers why Eroom's Law has made drug development slower and more expensive despite scientific advances, how the Montana model differs from existing right-to-try and expanded access programs, the thorny question of who pays when a treatment sits outside FDA approval and insurance coverage, the risks of messy observational data replacing randomized controlled trials, and how Anzinger's work connects to special economic zones like Prospera in Honduras, where he's speaking to the hosts from. Chapter Markers 00:22 Introducing Niklas Anzinger and his path from economics and VC to biotech policy 03:05 Montana SB535 explained — right-to-try, but with a for-profit pathway 06:01 Phase 1 vs phase 2 vs phase 3, and why bypass the later stages 11:37 Does SB535 cover devices as well as drugs 14:15 The semaglutide timeline as a case study in regulatory delay 18:36 Federal right-to-try, the baby KJ case, and why it isn't enough 23:25 The payment problem — how a non-FDA-approved treatment actually gets paid for 33:11 What "smart regulation" would look like with carte blanche over the FDA 48:31 Why Montana's biggest need right now is clinicians, not biotechs 49:57 The practical burden on a private practice running these treatments 53:32 Observational data vs. randomized trials — the risk of junk data 59:15 Is this a domestic answer to China's faster phase one pathway 1:04:22 Roatan, Prospera, and the case for special economic zones in medicine 1:09:18 Closing thoughts and where to find Anzinger's Stranded Technologies podcast Co-Host Handles @anish_koka and @DrDiGiorgio Show Handle @DRsLoungePod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Mr. Niklas Anzinger on X:  @NiklasAnzinger Mr. Niklas Anzinger Podcast: Stranded Technologies podcast 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode SummaryAnthony DiGiorgio and Anish Koka sit down with Dr. Dan Donoho, an NIH-funded neurosurgeon-scientist at Children's National Hospital and George Washington University, and founder of the Surgical Data Science Collective and the Foundation for Digital Neurosurgery, for a wide-ranging conversation on AI in medicine. Donoho explains why surgeons get almost no structured feedback after a case, walks through a randomized controlled trial showing AI-coached medical students outperformed those coached by humans on simulated tumor resections, and argues that most regulatory "barriers" to deploying AI in healthcare are cultural rather than statutory. The conversation moves through the limits of tactile sensation in surgical AI, why he expects innovation to come from small agile practices rather than large insurance-pay hospitals, his family's data science lineage, humanoid robots performing laparoscopic surgery, the anti-data-center backlash, and ongoing surgical AI trials in Ethiopia and Tanzania. Chapter Markers00:16 Introduction and guest background 01:16 The Surgical Data Science Collective and the problem of lost surgical knowledge 03:26 How AI could replace the mentor's voice in a surgeon's head 06:50 Tactile feedback and the limits of video-based AI in surgery 08:47 The RCT: AI coaching vs. human coaching in medical students 11:48 What's the gold standard for grading surgical performance 14:42 Who validates the AI — the EKG problem and patient outcomes as the real judge 17:19 Humanoid robots, self-driving cars, and low-hanging AI fruit in clinics 20:27 Regulatory barriers to AI in EHRs — culture vs. statute 22:09 Doctronic, AI prescribing, and licensure 25:12 Where Dan's interest in data science started 26:39 His father, statistician David Donoho, and the rise of empiricism 28:09 The "don't go into medicine" narrative and why it's wrong 30:26 COVID as a case study in bureaucratic drag on technology adoption 33:27 Should the FDA regulate surgical AI products 35:50 Andromeda Surgical, humanoid robots in the OR, and the cost gap 38:27 The anti-data-center movement and the history of sabotage 39:54 Global AI competition and China's Kimi K3 model 42:41 How to measure whether an AI model is actually better 44:34 Model size vs. training — why prompting changes performance 45:46 What the surgical community currently measures, and why it's the wrong thing 47:23 The Tanzania surgical AI trial and other real-world deployments 49:03 What actually scares Dan about AI 51:21 Will AI democratize power or concentrate it 52:15 Closing questions — what's next, including the Ethiopia partnership Co-Host Handle @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Dr. Daniel Donoho Website & X Website: https://www.surgicalvideo.io/ X: https://x.com/ddonoho 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode Summary Cardiothoracic surgeon Dr. George Tolis, chief of cardiothoracic surgery in Boston, returns to The Doctors Lounge with hosts Dr. Anish Koka and Dr. Anthony DiGiorgio for a wide-ranging conversation that opens with the newly proposed 2027 Medicare physician fee schedule and the budget-neutrality rule dating back to 1989 that forces cuts to one specialty to fund raises to another. The conversation moves into why true independent private practice has effectively disappeared, how hospital systems control physician hiring, firing, and pay regardless of what Medicare reimburses, and how locum tenens pay and device pricing expose the arbitrariness of professional fees. The back half of the episode turns to a widely discussed case of a cardiac valve implanted upside down in a young patient, with Tolis walking through how tunnel vision and ECMO can mask a never event for days, why he holds the surgeon fully accountable while condemning the social media pile-on that followed, and how palliative care should never be initiated without physician involvement. The episode closes on innovation in cardiac surgery — minimally invasive and robotic mitral repair, the Ross procedure, bilateral mammary artery use, valve selection, and how thirty-day outcome metrics quietly discourage surgeons from doing what's best for patients long-term — along with a candid discussion of industry money and conflicts of interest in medicine. Chapter Markers 00:00 Welcome back, Dr. George Tolis 01:09 The proposed 2027 physician fee schedule 05:20 Budget neutrality since 1989 and the flat physician bucket 10:09 Tolis: physicians are compensated less, not necessarily paid less 16:41 Barriers to going private and the PSA model 21:03 The painful transition to an independent physician ecosystem 25:25 Locum tenens pay, valve pricing, and "it's all by design" 33:51 The case: a valve placed upside down 40:01 Tunnel vision, distraction, and 110% concentration in the OR 50:45 Palliative care involvement and the organ-harvesting narrative 55:50 Reader comments: minimally invasive mitral surgery pushback 1:03:02 Competition, capitalism, and information asymmetry in medicine 1:13:02 Bio AVR vs. mechanical valve in a 57-year-old 1:15:28 Bilateral mammary arteries and the 30-day outcomes problem 1:17:46 Prospective payment, DRGs, and device cost incentives 1:25:08 Industry relationships and physician disclosures 1:29:05 GLP-1s, honoraria, and what counts as conflict of interest Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Dr. George Tolis's Previous Appearance on The Doctor's Lounge Dr. Tolis first joined The Doctor's Lounge about two months ago. Watch that episode here: https://x.com/DRsLoungePod/status/2055619280855515141?s=20 Dr. George Tolis on X @georgetolisjr 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X

Send us Fan Mail Episode SummaryDrs. Anish Koka and Anthony DiGiorgio sit down with independent science writer Cremieux, the pseudonymous Substack author known for auditing primary data and calling out flawed research. The conversation ranges from FDA drug approval reform (Cremieux proposes a two-pathway system separating safety approval from insurer-facing efficacy approval), the divide between well-evidenced GLP-1s and unregulated peptides like BPC-157, and the HRT black-box warning controversy, to the Columbia and NYU admissions data leaks that made national news and implicated NYC mayor Zohran Mamdani. The back half digs into research methodology: why observational studies rarely replicate RCT findings, how Cremieux debunked a widely-cited Jonathan Haidt social media/cognition study, why the "administrator growth" chart doctors love to cite is likely exaggerated, and how publication bias correction methods work. Chapter Markers00:00 Introduction and guest background 02:00 Why the pseudonym "Cremieux" 03:11 How he got into primary data analysis and writing 04:46 FDA drug approval reform — a two-pathway proposal 05:57 The peptide market: GLP-1s vs. unproven peptides like BPC-157 09:39 Should drug authority come from the FDA or "bubble up" from trusted voices? 11:25 Regulatory capture and ideas for FDA reform 16:10 HRT, the black box warning, and communicating risk to patients 21:40 Decentralizing medical decision-making 22:45 DEI in medicine and the Columbia/NYU admissions data leak 34:28 Proving discrimination: causal inference standards for university admissions 36:42 Busting myths from observational studies with multiverse analysis 40:29 Debunking the Jonathan Haidt social media/cognition study 46:46 Does the US healthcare system explain lower life expectancy? 49:56 Is the administrator-to-physician growth chart accurate? 54:22 How publication bias correction methods work Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod Subscribe Links Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658 YouTube: https://www.youtube.com/@TheDoctorsLoungePod Mr. Jordan Lasker X Handle / Substack X handle: https://x.com/cremieuxrecueil Substack: https://substack.com/@cremieux 🔗 Connect with the Hosts: • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X